Your browser doesn't support javascript.
loading
A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant.
Douketis, James D; Syed, Summer; Li, Na; Narouze, Samer; Radwi, Mansoor; Duncan, Joanne; Schulman, Sam; Spyropoulos, Alex C.
Afiliación
  • Douketis JD; Department of Medicine McMaster University Hamilton ON Canada.
  • Syed S; Department of Anesthesiology McMaster University Hamilton ON Canada.
  • Li N; Department of Medicine McMaster University Hamilton ON Canada.
  • Narouze S; Center for Pain Medicine Western Reserve Hospital Cuyahoga Falls OH USA.
  • Radwi M; Department of Hematology Faculty of Medicine University of Jeddah Jeddah Saudi Arabia.
  • Duncan J; Department of Medicine McMaster University Hamilton ON Canada.
  • Schulman S; Department of Medicine McMaster University Hamilton ON Canada.
  • Spyropoulos AC; Department of Obstetrics and Gynecology I.M. Sechenov First Moscow State Medical University Moscow Russia.
Res Pract Thromb Haemost ; 5(1): 159-167, 2021 Jan.
Article en En | MEDLINE | ID: mdl-33537540
BACKGROUND: The perioperative management of patients taking a direct oral anticoagulant (DOAC) who require a high-bleed-risk surgery and/or neuraxial anesthesia is uncertain. We surveyed clinician practices relating to DOAC interruption and related perioperative management in patients having high-bleed-risk surgery with neuraxial anesthesia, and assess the suitability of a randomized trial of different perioperative DOAC management strategies. METHODS: We surveyed members of the American Society of Regional Anesthesia and Pain Medicine, the Canadian Anesthesia Society and Thrombosis Canada. We developed four clinical scenarios involving DOAC-treated patients who required anticoagulant interruption for elective high-bleed-risk surgery. In three scenarios, patients were to receive neuraxial anesthesia, and in one scenario they were to receive general anesthesia. We also asked about the merit of a randomized trial to compare a 2-day versus longer (3- to 5-day) duration of DOAC interruption. RESULTS: There were 399 survey respondents of whom 356 (89%) were anesthetists and 43 (11%) were medical specialists. The responses indicate uncertainty about the DOAC interruption interval for high-bleed-risk surgery and/or neuraxial anesthesia; anesthetists favor 3- to 5-day interruption whereas medical specialists favor 2-day interruption. Anesthetists were unwilling to proceed with neuraxial anesthesia in patients with a 2-day DOAC interruption interval, preferring to cancel the surgery or switch to general anesthesia. There is general agreement on the need for a randomized trial in this field to compare a 2-day and a 3- to 5-day DOAC interruption management strategy. CONCLUSIONS: There is variability in practices relating to the perioperative management of DOAC-treated patients who require a high-bleed-risk surgery with neuraxial anesthesia; this variability relates to the duration of DOAC interruption in such patients.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Res Pract Thromb Haemost Año: 2021 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Res Pract Thromb Haemost Año: 2021 Tipo del documento: Article